Lilly, Sanofi Referred to HHS Watchdog Over Drug Discount Policy

Sept. 22, 2021, 10:15 PM

The Health Resources and Services Administration said Wednesday it reported six drugmakers to an HHS watchdog agency for limiting product discounts in a program geared for low-income Americans, claiming the companies are running afoul of government policy.

Lilly USA LLC, Novartis Pharmacuticals, and Novo Nordisk are among the companies HRSA called out for their “continued refusal to comply” with statutory obligations under the 340B program to give discounts to covered health-care providers dispensing medications through contract pharmacy arrangements, according to letters sent to the drugmakers Wednesday.

HRSA referred the companies, along with Sanofi, AstraZeneca and United Therapeutics, to the Health ...

To read the full article log in.

Learn more about a Bloomberg Law subscription.